{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:57:21Z","timestamp":1792511841649,"version":"4.5.0"},"reference-count":80,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Ifosfamide (IFO) is a nitrogen derivative used at different doses, alone or in combination, in the treatment of various types of solid and hematologic cancers. It is a pro-drug activated by cytochrome P450 enzymatic system into ifosforamide mustard, the alkylating component that carries out the cytotoxic effect of the IFO. The most common toxicities of IFO are gastrointestinal, cutaneous, hematological, urological, and neurological. The neurotoxicity may occur in up to 30% of patients and can manifest with a wide spectrum of clinical presentations (lethargy, somnolence, confusion, hallucinations, irritability, excitement, disorientation, weakness, seizures, movement disorders, coma) and a variety of EEG abnormalities, and is known as IFO-induced encephalopathy (IIE). There is no definitive explanation of the mechanism underlying this phenomenon, even though metabolism of IFO, which leads to the formation of neurotoxic components, is probably at the basis of neurotoxicity according to many hypotheses. Consequently, the different factors involved in IFO metabolism (i.e., genetic polymorphism of CYP2B6, GSTM1, GSTP1, and GSTT1; concomitant administration of drugs that affect the cytochrome P450 enzyme system; drug formulation) could be responsible of IIE. IIE is usually reversible by interrupting the IFO infusion and starting intravenous hydration but in some cases further interventions are needed. The most used pharmacological treatment is methylene blue, whose efficacy both as a curative and a prophylactic treatment has been the object of many studies, with mixed results. Other interventions that showed efficacy are thiamine (tested also as a prophylactic drug), dexmedetomidine, and hemodialysis. Other pharmaceuticals have been tested in a preclinical setting showing some activity: trifluoperazine, morin, caffeic acid phenethyl ester (CAPE), and alpha lipoic acid (ALA). The aim of this review is to gather the current knowledge about the mechanisms underlying the IIE and the current therapeutic approach and the future perspectives.<\/jats:p>","DOI":"10.3389\/fphar.2025.1512966","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T01:37:34Z","timestamp":1740101854000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["A narrative review on diagnosis and treatment of ifosfamide-induced encephalopathy, the perspective of a EURACAN reference center for sarcomas"],"prefix":"10.3389","volume":"16","author":[{"given":"A.","family":"Torchia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Vari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. E.","family":"Onesti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ceddia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Maschio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Maggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Riva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Faltyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Russillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Ferraresi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1177\/1078155220971843","article-title":"Methylene blue and ifosfamide-induced encephalopathy: myth or reality?","volume":"27","author":"Abahssain","year":"2021","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B2","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/1097-0142(19910701)68:1<72::aid-cncr2820680114>3.0.co;2-#","article-title":"Ifosfamide extrapyramidal neurotoxicity","volume":"68","author":"Anderson","year":"1991","journal-title":"Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1177\/10781552211005533","article-title":"Ifosfamide-related encephalopathy with severe clinical presentations in children with cancer","volume":"27","author":"Ataseven","year":"2021","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B4","doi-asserted-by":"publisher","first-page":"117085","DOI":"10.1016\/j.taap.2024.117085","article-title":"Chemotherapy-induced cognitive impairment and glia: a new take on chemobrain?","volume":"492","author":"Barbosa-Azevedo","year":"2024","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"B5","first-page":"4636","article-title":"Treatment of ifosfamide encephalopathy with intravenous thiamin","volume":"9","author":"Buesa","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/S0140-6736(85)91288-7","article-title":"Ifosfamide\/mesna and encephalopathy","volume":"325","author":"Cantwell","year":"1985","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s002800050720","article-title":"Toxicity, pharmacokinetics, and in vitro hemodialysis clearance of ifosfamide and metabolites in an anephric pediatric patient with Wilms\u2019 tumor","volume":"41","author":"Carlson","year":"1997","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.neuro.2019.11.004","article-title":"Morin attenuates ifosfamide-induced neurotoxicity in rats via suppression of oxidative stress, neuroinflammation and neuronal apoptosis","volume":"76","author":"\u00c7elik","year":"2020","journal-title":"NeuroToxicology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1093\/oxfordjournals.annonc.a058317","article-title":"The enigma of ifosfamide encephalopathy","volume":"3","author":"Cerny","year":"1992","journal-title":"Ann. Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12887-022-03144-1","article-title":"A novel case of prolonged Ifosfamide encephalopathy and long-term treatment with methylene blue: a case report and review of literature","volume":"22","author":"Chain","year":"2022","journal-title":"BMC Pediatr."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/s0022-3565(24)29242-9","article-title":"Insights into the mechanisms of ifosfamide encephalopathy:drug metabolites have agonistic effects on \u03b1-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)\/Kainate receptors and induce cellular acidification in mouse cortical neurons","volume":"299","author":"Chatton","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1177\/1078155212459285","article-title":"Ifosfamide-induced neurotoxicity reversal with continuous veno-venous hemodialysis. A case report","volume":"19","author":"Cherry","year":"2013","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B13","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0090-8258(91)90344-5","article-title":"Ifosfamide-induced neurotoxicity","volume":"42","author":"Curtin","year":"1991","journal-title":"Gynecol. Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3109\/15563658908994426","article-title":"Ifosfamide encephalopathy","volume":"27","author":"Danesh","year":"1989","journal-title":"J. Toxicol. Clin. Toxicol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1093\/bja\/aer009","article-title":"Anaphylactic reaction after methylene blue-treated plasma transfusion","volume":"106","author":"Dewachter","year":"2011","journal-title":"Br. J. Anaesth."},{"key":"B16","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1213\/01.ANE.0000153497.60047.80","article-title":"Severe anaphylactic shock with methylene blue instillation","volume":"101","author":"Dewachter","year":"2005","journal-title":"Anesth. and Analgesia"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1002\/1097-0142(19940301)73:5<1509::aid-cncr2820730531>3.0.co;2-g","article-title":"Hallucinations and ifosfamide-induced neurotoxicity","volume":"73","author":"DiMaggio","year":"1994","journal-title":"Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/fcp.12345","article-title":"Possible role of CYP2B6 genetic polymorphisms in ifosfamide-induced encephalopathy: report of three cases","volume":"32","author":"Duflot","year":"2018","journal-title":"Fundam. Clin. Pharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1093\/annonc\/mdm104","article-title":"Antiemetic neurokinin-1 antagonist aprepitant and ifosfamide-induced encephalopathy","volume":"18","author":"Durand","year":"2007","journal-title":"Ann. Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"5925","DOI":"10.2147\/DDDT.S91217","article-title":"Efficacy and safety of ifosfamide-based chemotherapy for osteosarcoma: a meta-analysis","volume":"9","author":"Fan","year":"2015","journal-title":"Drug Des. Devel Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jns.2013.10.018","article-title":"Ifosfamide related encephalopathy: the need for a timely EEG evaluation","volume":"336","author":"Feyissa","year":"2014","journal-title":"J. Neurological Sci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1093\/ndt\/16.5.1088","article-title":"Haemoperfusion combined with haemodialysis in ifosfamide intoxication","volume":"16","author":"Fiedler","year":"2001","journal-title":"Nephrol. Dial. Transplant."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1177\/1078155218808361","article-title":"Hydration, methylene blue, and thiamine as a prevention regimen for ifosfamide-induced encephalopathy","volume":"25","author":"Gharaibeh","year":"2019","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B24","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1177\/0748233713500817","article-title":"Protective effects of caffeic acid phenethyl ester on ifosfamide-induced central neurotoxicity in rats","volume":"32","author":"Ginis","year":"2016","journal-title":"Toxicol. Ind. Health"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/j.annonc.2021.07.006","article-title":"Soft tissue and visceral sarcomas: ESMO\u2013EURACAN\u2013GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2606","volume":"32","author":"Gronchi","year":"2021","journal-title":"Ann. Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/WNP.0000000000000539","article-title":"Clinical and EEG characteristics of ifosfamide-related encephalopathy","volume":"36","author":"Gusdon","year":"2019","journal-title":"J. Clin. Neurophysiology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1177\/1078155206073553","article-title":"Role of thiamine in managing ifosfamide-induced encephalopathy","volume":"12","author":"Hamadani","year":"2006","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B28","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1177\/1078155208093930","article-title":"Characterization of the occurrence of ifosfamide-induced neurotoxicity with concomitant aprepitant","volume":"14","author":"Howell","year":"2008","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B29","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/s0006-2952(99)00410-4","article-title":"Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide","volume":"59","author":"Huang","year":"2000","journal-title":"Biochem. Pharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"108366","DOI":"10.1016\/j.pharmthera.2023.108366","article-title":"Ifosfamide - history, efficacy, toxicity and encephalopathy","volume":"243","author":"Idle","year":"2023","journal-title":"Pharmacol. and Ther."},{"key":"B31","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1038\/bmt.2010.205","article-title":"The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (highdose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination","volume":"46","author":"Jordan","year":"2011","journal-title":"Bone Marrow Transpl."},{"key":"B32","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s00520-003-0573-2","article-title":"Prophylactic treatment of known ifosfamide-induced encephalopathy for chemotherapy with high-dose ifosfamide?","volume":"12","author":"Kasper","year":"2004","journal-title":"Support. Care Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2165\/00003088-200140010-00004","article-title":"Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites","volume":"40","author":"Kerbusch","year":"2001","journal-title":"Clin. Pharmacokinet."},{"key":"B34","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1592\/phco.30.8.812","article-title":"Effectiveness of exogenous albumin administration for the prevention of ifosfamide-induced encephalopathy","volume":"30","author":"Kettle","year":"2010","journal-title":"Pharmacotherapy"},{"key":"B35","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1055\/a-1154-8672","article-title":"Trifluoperazine an antipsychotic drug and inhibitor of mitochondrial permeability transition protects cytarabine and ifosfamide-induced neurotoxicity","volume":"70","author":"Kiani","year":"2020","journal-title":"Drug Res. (Stuttg)."},{"key":"B36","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s002280050102","article-title":"Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy","volume":"50","author":"K\u00fcpfer","year":"1996","journal-title":"E J. Clin. Pharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"575629","DOI":"10.1155\/2009\/575629","article-title":"Ifosfamide may Be safely used in patients with end stage renal disease on hemodialysis","volume":"2009","author":"Latcha","year":"2009","journal-title":"Sarcoma"},{"key":"B38","doi-asserted-by":"publisher","first-page":"368","DOI":"10.6004\/jadpro.2020.11.4.4","article-title":"Risk factors for ifosfamide-related encephalopathy in adult cancer patients: an integrative review","volume":"11","author":"Lee","year":"2020","journal-title":"JADPRO"},{"key":"B39","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"B40","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1177\/1078155219859644","article-title":"Evaluation of thiamine for the prevention of ifosfamide-induced encephalopathy","volume":"26","author":"Lentz","year":"2020","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B41","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.toxlet.2005.09.002","article-title":"Cerebral formation in situ of S-carboxymethylcysteine after ifosfamide administration to mice: a further clue to the mechanism of ifosfamide encephalopathy","volume":"161","author":"Lerch","year":"2006","journal-title":"Toxicol. Lett."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.bcp.2010.06.002","article-title":"Comparative metabolism of cyclophosphamide and ifosfamide in the mouse using UPLC-ESI-QTOFMS-based metabolomics","volume":"80","author":"Li","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.jfma.2015.07.016","article-title":"Risk factors of ifosfamide-related encephalopathy in adult patients with cancer: a retrospective analysis","volume":"115","author":"Lo","year":"2016","journal-title":"J. Formos. Med. Assoc."},{"key":"B44","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/s0140-6736(86)90099-1","article-title":"Avoiding ifosfamide\/mesna encephalopathy","volume":"328","author":"Meanwell","year":"","journal-title":"Lancet"},{"key":"B45","first-page":"727","article-title":"Phase II study of ifosfamide in cervical cancer","volume":"70","author":"Meanwell","year":"","journal-title":"Cancer Treat. Rep."},{"key":"B46","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1097\/MPH.0000000000002473","article-title":"Ifosfamide-induced encephalopathy with rapid response to thiamine: a pediatric case","volume":"44","author":"M\u00fcngen","year":"2022","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy \u2014 assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s10047-013-0733-1","article-title":"Effects of blood purification therapy on a patient with ifosfamide-induced neurotoxicity and acute kidney injury","volume":"17","author":"Nishimura","year":"2014","journal-title":"J. Artif. Organs"},{"key":"B49","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/j.1537-2995.2010.02800.x","article-title":"Anaphylactic shock to fresh-frozen plasma inactivated with methylene blue","volume":"51","author":"Nubret","year":"2011","journal-title":"Transfusion"},{"key":"B50","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3109\/00207454.2013.823962","article-title":"Effect of alpha lipoic acid on ifosfamide-induced central neurotoxicity in rats","volume":"124","author":"Ozturk","year":"2014","journal-title":"Int. J. Neurosci."},{"key":"B51","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1111\/bcp.13322","article-title":"Aprepitant and fosaprepitant drug interactions: a systematic review","volume":"83","author":"Patel","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1345\/aph.1G114","article-title":"Methylene blue for management of ifosfamide-induced encephalopathy","volume":"40","author":"Patel","year":"2006","journal-title":"Ann. Pharmacother."},{"key":"B53","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1177\/030089160509100218","article-title":"Ifosfamide encephalopathy: a case report","volume":"91","author":"Pavarana","year":"2005","journal-title":"Tumori"},{"key":"B54","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1054\/bjoc.1999.0917","article-title":"Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature","volume":"82","author":"Pelgrims","year":"2000","journal-title":"Br. J. Cancer"},{"key":"B55","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1017\/s0317167100120980","article-title":"Ifosfamide encephalopathy and nonconvulsive status epilepticus","volume":"29","author":"Primavera","year":"2002","journal-title":"Can. J. Neurol. Sci."},{"key":"B56","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00134-015-4124-3","article-title":"The reliability of the Glasgow Coma Scale: a systematic review","volume":"42","author":"Reith","year":"2016","journal-title":"Intensive Care Med."},{"key":"B57","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1177\/1078155210385159","article-title":"Evaluation of methylene blue, thiamine, and\/or albumin in the prevention of ifosfamide-related neurotoxicity","volume":"17","author":"Richards","year":"2011","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B58","first-page":"333","article-title":"Aprepitant--where do we stand in the control of chemotherapy-induced nausea and vomiting?","volume":"13","author":"Sarcev","year":"2008","journal-title":"J. BUON"},{"key":"B59","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/0305-7372(90)90060-s","article-title":"Modulation of cytotoxicity of cytostatic drugs by hemodialysis in vitro and in vivo","volume":"17","author":"Sauer","year":"1990","journal-title":"Cancer Treat. Rev."},{"key":"B60","doi-asserted-by":"publisher","first-page":"5798","DOI":"10.3390\/jcm11195798","article-title":"Inflammatory surrogate parameters for predicting ifosfamide-induced neurotoxicity in sarcoma patients","volume":"11","author":"Schmidt","year":"2022","journal-title":"JCM"},{"key":"B61","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1159\/000368184","article-title":"Two cases of fatal encephalopathy related to ifosfamide: an adverse role of aprepitant","volume":"7","author":"S\u00e9journ\u00e9","year":"2014","journal-title":"Case Rep. Oncol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1177\/0091270003262950","article-title":"Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity","volume":"44","author":"Shadle","year":"2004","journal-title":"J. Clin. Pharmacol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.gynor.2013.06.002","article-title":"The interaction of ifosfamide and aprepitant in gynecologic malignancies","volume":"6","author":"Shindorf","year":"2013","journal-title":"Gynecol. Oncol. Case Rep."},{"key":"B64","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1001\/archpedi.1994.02170030076017","article-title":"Methylene blue\u2013induced Heinz body hemolytic anemia","volume":"148","author":"Sills","year":"1994","journal-title":"Archives Pediatr. and Adolesc. Med."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1073274817729070","DOI":"10.1177\/1073274817729070","article-title":"Serotonin syndrome complicating treatment of ifosfamide neurotoxicity with methylene blue","volume":"24","author":"Snyder","year":"2017","journal-title":"Cancer control."},{"key":"B66","doi-asserted-by":"publisher","first-page":"vdad135","DOI":"10.1093\/noajnl\/vdad135","article-title":"Functional connectivity MRI provides an imaging correlate for chimeric antigen receptor T-cell-associated neurotoxicity","volume":"5","author":"Stoecklein","year":"2023","journal-title":"Neuro-Oncology Adv."},{"key":"B67","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1124\/jpet.108.144170","article-title":"New ifosfamide analogs designed for lower associated neurotoxicity and nephrotoxicity with modified alkylating kinetics leading to enhanced in vitro anticancer activity","volume":"328","author":"Storme","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1016\/j.annonc.2021.08.1995","article-title":"Bone sarcomas: ESMO\u2013EURACAN\u2013GENTURIS\u2013ERN PaedCan clinical practice guideline for diagnosis, treatment and follow-up","volume":"32","author":"Strauss","year":"2021","journal-title":"Ann. Oncol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1177\/1078155214527143","article-title":"An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center","volume":"21","author":"Szabatura","year":"2015","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B70","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s00776-009-1431-y","article-title":"Ifosfamide encephalopathy associated with chemotherapy for musculoskeletal sarcomas: incidence, severity, and risk factors","volume":"15","author":"Tajino","year":"2010","journal-title":"J. Orthop. Sci."},{"key":"B71","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/s0936-6555(03)00114-6","article-title":"Methylene blue for the treatment and prophylaxis of ifosfamide-induced encephalopathy","volume":"15","author":"Turner","year":"2003","journal-title":"Clin. Oncol."},{"key":"B72","first-page":"921","article-title":"Unexpected toxicity in patients treated with iphosphamide","volume":"32","author":"van Dyk","year":"1972","journal-title":"Cancer Res."},{"key":"B73","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1002\/ajh.25028","article-title":"Methylene blue-induced Heinz body hemolytic anemia in a premature neonate","volume":"93","author":"Vanhinsbergh","year":"2018","journal-title":"Am. J. Hematol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00280-022-04439-x","article-title":"Aprepitant, fosaprepitant and risk of ifosfamide-induced neurotoxicity: a systematic review","volume":"90","author":"Vazirian","year":"2022","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/0277-5379(89)90077-1","article-title":"Ifosfamide encephalopathy: a reappraisal","volume":"25","author":"Watkin","year":"1989","journal-title":"Eur. J. Cancer Clin. Oncol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s12325-018-0862-2","article-title":"Efficacy, tolerability and pharmacokinetic impact of aprepitant in sarcoma patients receiving ifosfamide and doxorubicin chemotherapy: a randomized controlled trial","volume":"36","author":"Xiong","year":"2019","journal-title":"Adv. Ther."},{"key":"B77","doi-asserted-by":"publisher","first-page":"e613","DOI":"10.1097\/MJT.0000000000001189","article-title":"Delayed ifosfamide neurotoxicity","volume":"27","author":"Yeager","year":"2020","journal-title":"Am. J. Ther."},{"key":"B78","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1097\/MPH.0000000000000527","article-title":"The use of continuous veno-venous hemodiafiltration in the management of ifosfamide-induced encephalopathy: a case report","volume":"38","author":"Yeo","year":"2016","journal-title":"J. Pediatr. Hematology\/Oncology"},{"key":"B79","doi-asserted-by":"publisher","first-page":"521","DOI":"10.3389\/fphar.2016.00521","article-title":"Cerebral gluconeogenesis and diseases","volume":"7","author":"Yip","year":"2017","journal-title":"Front. Pharmacol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1097\/01.mph.0000187429.52616.8a","article-title":"Role of GSTM1, GSTP1, and GSTT1 gene polymorphism in ifosfamide metabolism affecting neurotoxicity and nephrotoxicity in children","volume":"27","author":"Zieli\u0144ska","year":"2005","journal-title":"J. Pediatr. Hematology\/Oncology"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1512966\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T01:37:39Z","timestamp":1740101859000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1512966\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,21]]},"references-count":80,"alternative-id":["10.3389\/fphar.2025.1512966"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1512966","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,21]]},"article-number":"1512966"}}